Panacea Biotec Ltd

NSE: PANACEABIO · BSE: 531349 · Pharmaceuticals & Biotechnology · 31 announcements

Share price: ₹353.70
Market cap: ₹2,166 Cr
Revenue (annual): ₹639.8 Cr
Net profit (annual): ₹-5.38 Cr
P/E (TTM): -304.3×Sector 43.8×
Promoter holding: 72.48%+0.00% QoQ
FII holding: 2.75%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Legal & Regulatory 5 Promoter Buying (Off-Market) 3 Other Announcement 3 Financial Results 3 Board Meeting Date 3 New Order Win 2 Annual General Meeting 2 Management Change 1 Capital Structure Change 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

5 Aug 2026 09:39 IST BSE

New Order Win

Panacea Biotec Bags ₹78.24 Cr Order

Panacea Biotec Ltd secured a Letter of Award from UNICEF worth approximately Rs.78.24 Crore ($8.205 million). The contract involves supplying bivalent Oral Polio Vaccine during 2028.

Value: ₹78.24 Cr
Execution: Calendar Year 2028

Open announcement → Read the filing ↗

8 Jun 2026 18:22 IST NSE

New Order WinAlfa Alert

Panacea Biotec Bags ₹120.9 Cr Order

Panacea Biotec joined the €11.1 million (₹120.90 Crore) EU-funded DENSTAR consortium. The 48-month project advances licensure of its DengiAll vaccine in sub-Saharan Africa.

Value: ₹120.9 Cr
Execution: 48 months

Open announcement → Read the filing ↗